Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Collegium Pharmaceutical Inc    COLL

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
10.45(c) 10.53(c) 10.46(c) 10.31(c) 10.07 Last
296 844 408 257 281 239 307 520 436 208 Volume
+1.06% +0.77% -0.66% -1.43% -2.33% Change
More quotes
Financials ($)
Sales 2017 19,3 M
EBIT 2017 -89,0 M
Net income 2017 -89,3 M
Debt 2017 63,0 M
Yield 2017 -
Sales 2018 59,4 M
EBIT 2018 -60,8 M
Net income 2018 -56,0 M
Finance 2018 1,00 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 19,0x
EV / Sales2018 5,11x
Capitalization 305 M
More Financials
Company
Collegium Pharmaceutical, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of proprietary, late stage pharmaceutical products.These products target market opportunities through formulation based product improvements protected by intellectual property.It builds a... 
Sector
Pharmaceuticals
Calendar
11/16Earnings Release
More about the company
Surperformance© ratings of Collegium Pharmaceutical I
Trading Rating : Investor Rating :
More Ratings
Latest news on COLLEGIUM PHARMACEUTICAL I
08/09 COLLEGIUM PHARMACEUTICAL,INC. (NASDA : COLL) Files An 8-K Results of Operations ..
08/09 COLLEGIUM PHARMACEUTICAL, INC : Results of Operations and Financial Condition, C..
08/09 COLLEGIUM PHARMACEUTICAL : posts 2Q loss
08/09 COLLEGIUM PHARMACEUTICAL : Management's Discussion and Analysis of Financial Con..
08/09 Collegium Reports Second Quarter Financial Results and Provides Corporate Upd..
08/09 COLLEGIUM PHARMACEUTICAL INC : Investor Network: Collegium Pharmaceutical, Inc. ..
07/18 Collegium to Host Conference Call to Discuss Second Quarter 2017 Financial Re..
06/29 COLLEGIUM PHARMACEUTICAL : Patent Issued for Tamper-Resistant Pharmaceutical Com..
06/24 COLLEGIUM PHARMACEUTICAL : U.S. Patents Awarded to Inventors in Rhode Island (Ju..
06/24 COLLEGIUM PHARMACEUTICAL : U.S. Patents Awarded to Inventors in Connecticut (Jun..
More news
Sector news : Pharmaceuticals - NEC
01:15pDJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08:35aDJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/17 Exclusive - Taking aim at China, India tightens power grid, telecoms rules
More sector news : Pharmaceuticals - NEC
Latest Tweets
08/15Collegium Pharmaceutical upgraded by Zacks Investment Research to hold.  
08/14Gabelli Raises Collegium Pharmaceutical FY2017 Earnings Estimates to ($2.90) .. 
08/14William Blair Comments on Collegium Pharmaceutical, Inc.’s Q3 2017 Earnings $.. 
08/14Jefferies Group LLC Lowers Collegium Pharmaceutical Q3 2017 Earnings Estimate.. 
08/12UBS Group AG Increases Position in Collegium Pharmaceutical, Inc. $COLL  
More tweets
Qtime:11
News from SeekingAlpha
08/11 WALL STREET BREAKFAST : Worst Week For Equities In 2017
08/09 Collegium Pharmaceutical's (COLL) CEO Mike Heffernan on Q2 2017 Results - Ear..
08/09 Collegium Pharmaceutical beats by $0.09, misses on revenue
08/03 Generic drug firms feel Teva's pain
06/26 THE OPIOID ABUSE EPIDEMIC : What's The Investment Angle?
Chart COLLEGIUM PHARMACEUTICAL I
Duration : Period :
Collegium Pharmaceutical I Technical Analysis Chart | COLL | US19459J1043 | 4-Traders
Technical analysis trends COLLEGIUM PHARMACEUTICAL I
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 18,8 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
Michael Thomas Heffernan Chairman, President & Chief Executive Officer
Joseph J. Ciaffoni Chief Operating Officer & Executive Vice President
Paul Brannelly Chief Financial Officer & Executive Vice President
Gino Santini Independent Director
David J. Hirsch Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
COLLEGIUM PHARMACEUTICAL INC-32.82%305
JOHNSON & JOHNSON15.48%357 079
ROCHE HOLDING LTD.5.37%218 752
NOVARTIS10.59%218 545
PFIZER1.45%196 221
MERCK AND COMPANY5.05%168 660